An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer

被引:3
作者
Finch, Lindsey [1 ]
Chi, Dennis S. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Weill Cornell Med Coll, Dept Obstet & Gynecol, New York, NY USA
关键词
Epithelial Ovarian Cancer; Laparotomy; Minimally Invasive Surgery; Cytoreductive Surgery; PORT-SITE METASTASES; NEOADJUVANT CHEMOTHERAPY; DEBULKING SURGERY; OPEN-LABEL; LAPAROSCOPY; WOMEN;
D O I
10.3802/jgo.2023.34.e84
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The standard of care for treatment of advanced-stage epithelial ovarian cancer is primarily surgery followed by platinum-based chemotherapy, with the operative goal to achieve complete gross resection. Cytoreductive surgeries for epithelial ovarian cancer historically were performed via open laparotomy; however, as minimally invasive techniques became more widely accepted within gynecologic oncology, interest in employing this approach in the setting of cytoreductive surgery for epithelial ovarian cancer has grown. The purpose of this review was to examine the current debate between the use of minimally invasive surgery versus laparotomy as an approach to interval cytoreductive surgery in advanced epithelial ovarian cancer. While numerous retrospective and feasibility studies have found comparable outcomes with respect to complete gross residual disease, progression-free survival, and overall survival between minimally invasive and laparotomy approaches to interval cytoreductive surgery for epithelial ovarian cancer, methodological challenges limit the utility of these data. Given potential risks of underestimating disease burden and failing to achieve complete resection using a minimally invasive approach, further rigorous studies are needed to evaluate the safety and efficacy of minimally invasive surgery in this setting and to better define the subset of patients who would receive the greatest benefit from a minimally invasive approach.
引用
收藏
页数:9
相关论文
共 30 条
  • [1] Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy
    Abitbol, Jeremie
    Gotlieb, Walter
    Zeng, Ziggy
    Ramanakumar, Agnihotram
    Kessous, Roy
    Kogan, Liron
    Pare-Miron, Valerie
    Rombaldi, Marcelo
    Salvador, Shannon
    Kucukyazici, Beste
    Brin, Sonya
    How, Jeffrey
    Lau, Susie
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (09) : 1341 - 1347
  • [2] Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study
    Alletti, S. Gueli
    Petrillo, M.
    Vizzielli, G.
    Bottoni, C.
    Nardelli, F.
    Costantini, B.
    Quagliozzi, L.
    Gallotta, V.
    Scambia, G.
    Fagotti, A.
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 143 (03) : 516 - 520
  • [3] Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study
    Alletti, Salvatore Gueli
    Bottoni, Carolina
    Fanfani, Francesco
    Gallotta, Valerio
    Chiantera, Vito
    Costantini, Barbara
    Cosentino, Francesco
    Ercoli, Alfredo
    Scambia, Giovanni
    Fagotti, Anna
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (04) : 503.e1 - 503.e6
  • [4] When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer
    Brown, Jubilee
    Drury, Lane
    Crane, Erin K.
    Anderson, William E.
    Tait, David L.
    Higgins, Robert, V
    Naumann, R. Wendel
    [J]. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2019, 26 (05) : 902 - 909
  • [5] Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis
    Cardenas-Goicoechea, Joel
    Wang, Yu
    McGorray, Susan
    Saleem, Mohammed D.
    Mamani, Semiramis L. Carbajal
    Pomputius, Ariel F.
    Markham, Merry-Jennifer
    Castagno, Jacqueline C.
    [J]. JOURNAL OF ROBOTIC SURGERY, 2019, 13 (01) : 23 - 33
  • [6] Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
    Chi, Dennis S.
    Eisenhauer, Eric L.
    Zivanovic, Oliver
    Sonoda, Yukio
    Abu-Rustum, Nadeem R.
    Levine, Douglas A.
    Guile, Matthew W.
    Bristow, Robert E.
    Aghajanian, Carol
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 114 (01) : 26 - 31
  • [7] The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy
    Fagotti, A.
    Alletti, S. Gueli
    Corrado, G.
    Cola, E.
    Vizza, E.
    Vieira, M.
    Andrade, C. E.
    Tsunoda, A.
    Favero, G.
    Zapardiel, I.
    Pasciuto, T.
    Scambia, G.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (01) : 5 - 9
  • [8] Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
    Fagotti, Anna
    Ferrandina, Maria Gabriella
    Vizzielli, Giuseppe
    Pasciuto, Tina
    Fanfani, Francesco
    Gallotta, Valerio
    Margariti, Pasquale Alessandro
    Chiantera, Vito
    Costantini, Barbara
    Gueli Alletti, Salvatore
    Cosentino, Francesco
    Scambia, Giovanni
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1657 - 1664
  • [9] Laparoscopy versus laparotomy for FIGO stage I ovarian cancer
    Falcetta, Frederico S.
    Lawrie, Theresa A.
    Medeiros, Lidia R. F.
    da Rosa, Maria Ines
    Edelweiss, Maria I.
    Stein, Airton T.
    Zelmanowicz, Alice
    Moraes, Anaelena B.
    Zanini, Roselaine R.
    Rosa, Daniela D.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (10):
  • [10] Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical?
    Filippova, O. T.
    Broach, V.
    Gardner, G. J.
    Sonoda, Y.
    Zivanovic, O.
    Chi, D. S.
    Roche, K. Long
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 142 - 143